Sustainability Report 2012 Lek d.d.

Company Profile Sustainability Report 2012 – Lek d.d. 10 1.3 About us Lek, 7 a Sandoz company, is a joint-stock company, 100% owned by Novartis Pharma AG. It is based in Ljubljana, it has its development centers in Ljubljana and Menge‰, and ope- rates at four production sites: Ljubljana, Menge‰, Prevalje and Lendava. In 2012, all the sites became EMAS certified, and registered in the EMAS Register. Lek develops, manufactures and markets effective, safe and quality medicinal products, from standard generic drugs through to state-of-the-art biosimilars. For more information about Lek, please visit www.lek.si/en . Sandoz, the generic division of the Novartis Group, is a global leader in the fast-growing industry of generic phar- maceuticals, offering a wide array of approximately 1,100 high-quality, affordable products that are no longer protec- ted by patents. With nearly 26,000 employees in approxi- mately 140 countries, Sandoz holds the leading position globally in biosimilars, injectables, ophthalmics and derma- tology as well as a strong global No.5 position in inhala- bles. Key product groups include antibiotics, treatments for central nervous systemdisorders, gastrointestinal medicines, cardiovascular treatments, and hormone therapies. Sandoz develops, produces, and markets these medicines along with pharmaceutical and biotechnological active substances and anti-infectives. In addition to strong organic growth in recent years, Sandoz has made a series of acquisitions including Lek (Slovenia), Sabex (Canada), Hexal (Germany), Eon Labs (US), EBEWE Pharma (Austria), Oriel Therapeutics (US), and Fougera Pharmaceuticals (US). In 2012, Sandoz posted sales of USD 8.7 billion. For more information, please visit www.sandoz.com . * Sandoz is on Twitter. Follow @Sandoz_global at: t witter.com/sandoz . Novartis provides innovative healthcare solutions that ad- dress the evolving needs of patients and societies. Head- quartered in Basel, Switzerland, Novartis offers a highly diversified drug portfolio: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2012, the Group achieved net sales of USD 56.7 billion, while R&D throughout the Group amounted to approximately USD 9.3 billion (USD 9.1 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 128,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit www.novartis.com . * Novartis is on Twitter. Follow @Novartis at: twitter.com/novartis . Lek is a pharmaceutical company, one of the pillars of Sandoz, the generic division of the Novartis Group and the second-largest global generics manufacturer. Within Sandoz, Lek has the following functions: • Global development center for products and technologies, • One of the key global manufacturing center for APIs and medicines, • Competence center for the development of vertically-integrated products, • Sandoz' competence center for the development and manufacture of biopharmaceuticals, • Supply center for the markets of CEE, SEE and CIS, and • Responsibility for the marketing and sales of Sandoz products in Slovenia. 7 Disclosures GRI 2.3 and 2.6